Ad Code

Responsive Advertisement

Ticker

6/recent/ticker-posts

Three-year study of tirzepatide shows that most patients only regain 5% or less from their lowest weight

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around two-thirds of participants of the SURMOUNT-1 trial had only regained 5% or less of their so-called nadir (or lowest weight) three years after beginning treatment with tirzepatide.

from Medical Xpress - latest medical and health news stories https://ift.tt/K7OIpWc